TIDMFDBK

RNS Number : 4448R

Feedback PLC

26 October 2023

Feedback plc

Result of AGM

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that at the Annual General Meeting ("AGM") held today all resolutions were duly passed.

The results of the poll (including proxy votes on the resolutions) are included below.

 
 Resolutions          Votes For**   % of votes       Votes Against   % of votes       Votes            Total votes 
                                    cast***                          cast***          Withheld***      cast*** 
      1) To receive 
       the report 
       and accounts 
       for the year 
       ended 31 May 
       2023.           6,796,610        99.94           4,120            0.06               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      2) To receive 
       the 
       remuneration 
       report of 
       the Company 
       for the year 
       ended 31 May 
       2023.           6,793,069        99.89           7,661            0.11               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      3) To 
       re-elect 
       Adam Denning 
       as a 
       Director of 
       the Company.    6,794,360        99.91           6,370            0.09               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      4) To 
       re-elect 
       Philipp 
       Prince as a 
       Director of 
       the Company.    6,794,360        99.91           6,370            0.09               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      5) To 
       re-appoint 
       Price Bailey 
       LLP as 
       Auditor of 
       the Company.    6,796,610        99.94           4,120            0.06               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      6) To 
       authorise 
       the 
       Directors to 
       determine 
       the fees 
       payable to 
       the Auditor.    6,796,610        99.94           4,120            0.06               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
                                                   Special Business 
      7) To 
       authorise 
       the 
       Directors to 
       allot equity 
       securities.     6,794,094        99.90           6,636            0.10               64            6,800,730 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      Special 
       Resolution 
       8) To 
       empower the 
       Directors to 
       allot equity 
       securities 
       for cash 
       free of 
       statutory 
       pre-emption 
       rights.         6,794,093        99.90           6,636            0.10               65            6,800,729 
                     ------------  ---------------  --------------  ---------------  ----------------  --------------- 
      Special 
       resolution 
       9) To 
       empower the 
       Directors to 
       allot equity 
       securities 
       for cash 
       otherwise 
       than on a 
       pre-emptive 
       basis for an 
       acquisition 
       or other 
       capital 
       investment.     6,794,093        99.90           6,636            0.10               65            6,800,729 
 
 

Notes:

* "Votes For" include votes giving the Chairman discretion.

** Percentages exclude "Votes Withheld".

*** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution.

**** "Total votes cast" do not include withheld votes.

-Ends-

Enquiries:

 
 Feedback plc                             +44 (0) 20 3997 7634 
  Tom Oakley, CEO                          IR@fbk.com 
  Anesh Patel, CFO 
 
 Panmure Gordon (UK) Limited 
  (NOMAD and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)      +44 (0)20 7886 2500 
 
 Walbrook PR Ltd;                         Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Nick Rome/Joe Walker                     07748 325 236 or 07407 020 470 
 

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGXQLFLXBLLFBX

(END) Dow Jones Newswires

October 26, 2023 09:24 ET (13:24 GMT)

Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Feedback Charts.
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Feedback Charts.